ISSN 1671-5411 CN 11-5329/R
Online Office
Current Issue
In-hospital outcomes and readmission in older adults treated with percutaneous coronary intervention for stable ischemic heart disease
Dae Yong Park, Jonathan M. Hanna, Sumeet Kadian, Mannat Kadian, W. Schuyler Jones, Abdulla Al Damluji, Ajar Kochar, Jeptha P. Curtis, Michael G. Nanna
2022, 19(9): 631-642.   doi: 10.11909/j.issn.1671-5411.2022.09.006
Abstract(2) FullText HTML(0) PDF (0)
A short P-wave duration is associated with incident heart failure in the elderly: a 15 years follow-up cohort study
Bozena Ostrowska, Lars Lind, Elena Sciaraffia, Carina Blomström-Lundqvist
2022, 19(9): 643-650.   doi: 10.11909/j.issn.1671-5411.2022.09.008
Abstract(0) FullText HTML(0) PDF (0)
The interaction effect of grip strength and lung function (especially FVC) on cardiovascular diseases: a prospective cohort study in Jiangsu Province, China
Jia-Li LIU, Jia-Qi WANG, Dan WANG, Yu QIN, Yong-Qing ZHANG, Quan-Yong XIANG
2022, 19(9): 651-659.   doi: 10.11909/j.issn.1671-5411.2022.09.007
Abstract(0) FullText HTML(0) PDF (0)
Association between heart failure severity and mobility in geriatric patients: an in-clinic study with wearable sensors
Tobias Braun, Anna Wiegard, Johanna Geritz, Clint Hansen, Kim Eng Tan, Hanna Hildesheim, Jennifer Kudelka, Corina Maetzler, Julius Welzel, Robbin Romijnders, Walter Maetzler, Philipp Bergmann
2022, 19(9): 660-674.   doi: 10.11909/j.issn.1671-5411.2022.09.010
Abstract(0) FullText HTML(0) PDF (0)
Iatrogenic atrial septal defects after transseptal puncture for percutaneous left atrial appendage occlusion and their hemodynamic effects
Ioannis Drosos, Roberta De Rosa, Philipp C. Seppelt, Sebastian Cremer, Silvia Mas-Peiro, Katrin Hemmann, Jana Oppermann, Recha Blessing, Mariuca Vasa-Nicotera, Andreas M. Zeiher, Zisis Dimitriadis
2022, 19(9): 675-684.   doi: 10.11909/j.issn.1671-5411.2022.09.009
Abstract(2) FullText HTML(0) PDF (0)
Early identification of STEMI patients with emergency chest pain using lipidomics combined with machine learning
Zhi SHANG, Yang LIU, Yu-Yao YUAN, Xin-Yu WANG, Hai-Yi YU, Wei GAO
2022, 19(9): 685-695.   doi: 10.11909/j.issn.1671-5411.2022.09.003
Abstract(0) FullText HTML(0) PDF (0)
Complement use of Chinese herbal medicine after percutaneous coronary intervention: a prospective observational study
Si-Yu YAN, Wei-Xian YANG, Pei-Pei LU, Xuan-Tong GUO, Cai-Xia GUO, Yan-Ni SU, Li-Hong MA
2022, 19(9): 696-704.   doi: 10.11909/j.issn.1671-5411.2022.09.005
Abstract(1) FullText HTML(0) PDF (0)
Efficacy of vasopressin, steroid, and epinephrine protocol for in-hospital cardiac arrest resuscitation: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Danish Iltaf Satti, Yan Hiu Athena Lee, Keith Sai Kit Leung, Jeremy Man Ho Hui, Thompson Ka Ming Kot, Arslan Babar, Gauranga Mahalwar, Abraham KC Wai, Tong Liu, Leonardo Roever, Gary Tse, Jeffrey Shi Kai Chan
2022, 19(9): 705-711.   doi: 10.11909/j.issn.1671-5411.2022.09.002
Abstract(4) FullText HTML(1) PDF (0)
Risk of pacemaker implantation after femur fracture in patients with and without a history syncope: a Danish nationwide registry-based follow-up study
Sara LK Clemmensen, Kristian Kragholm, Bhupendar Tayal, Christian Torp-Pedersen, Søren Kold, Peter Søgaard, Sam Riahi
2022, 19(9): 712-718.   doi: 10.11909/j.issn.1671-5411.2022.09.001
Abstract(0) FullText HTML(0) PDF (0)
Determinants of mortality among seniors acutely readmitted for heart failure: racial disparities and clinical correlations
Tuoyo O Mene-Afejuku, Gini P Jeyashanmugaraja, Mahfuz Hoq, Olatunde Ola, Amit J Shah
2022, 19(9): 719-724.   doi: 10.11909/j.issn.1671-5411.2022.09.004
Abstract(1) FullText HTML(0) PDF (0)
Online First
Guang-Yao ZHAI, Zheng CHEN, Rui-Fang LIU, Yong-He GUO, Jian-Long WANG, Tie-Nan SUN, Jing XIE, Tao HUANG, Yu-Jie ZHOU
 doi: 10.11909/j.issn.1671-5411.2022.10.002
Abstract(0) FullText HTML(0) PDF (0)
 BACKGROUND  Several studies have proved the safety and feasibility of robot-assisted percutaneous coronary intervention (PCI) in reducing the occupational hazards of interventionists while achieving precision medicine. However, an independently developed robot-assisted system for PCI in China has not yet emerged. This study aimed to evaluate the safety and feasibility of a robot-assisted system for elective PCI in China.  METHODS  This preclinical trial included 22 experimental pigs and preliminarily supported the safety and feasibility of the ETcath200 robot-assisted system for PCI. Then, eleven patients with coronary heart disease who met the inclusion criteria and had clinical indications for elective PCI were enrolled. PCI was performed using a robot-assisted system. The primary outcomes were clinical success (defined as visual estimated residual stenosis < 30% after PCI and no major adverse cardiovascular events during hospitalization and within 30 days after PCI) and technical success (defined as the ability to use the robot-assisted system to complete PCI successfully without conversion to the traditional manual PCI).  RESULTS  Eleven patients were included in this clinical trial. A drug-eluting stent with a diameter of 3 mm (interquartile range: 2.75–3.5 mm) and a length of 26 mm (interquartile range: 22–28 mm) was deployed in all patients. The clinical success rate was 100%, with no PCI-related complications and no in-hospital or 30-day major adverse cardiovascular events, and the technical success rate was 100%.  CONCLUSIONS  The results strongly suggest that the use of the independently developed robot-assisted system in China for elective PCI is feasible, safe, and effective.
Zhong-Jing CAO, Xiao-Gang GUO, Qi SUN, Yan-Qiao CHEN, Hai-Yang XIE, Jian-Du YANG, Hui-Qiang WEI, Jia-Hui LI, Jian MA
 doi: 10.11909/j.issn.1671-5411.2022.10.001
Abstract(33) FullText HTML(12) PDF (0)
 BACKGROUND  Pulmonary vein isolation (PVI) alone for persistent atrial fibrillation (PersAF) remains controversial. The characteristics of cryoballoon ablation (CBA) to treat PersAF and the blanking period recurrence are underreported.  METHODS  This study retrospectively analyzed patients with PersAF undergoing second-generation CBA for de novo PVI. The post-procedural efficacy and survival analysis were compared between patients with different PersAF durations. The multivariate Cox regression analysis was used to detect the risk factors for recurrence. Early and long-term recurrence were analyzed relative to each other.  RESULTS  A total of 329 patients were enrolled, with a median PersAF duration of 4.0 months (interquartile range: 2.0–12.0 months); 257 patients (78.1%) were male. Kaplan-Meier analysis of freedom from atrial fibrillation recurrence at 12, 24, and 30 months showed 71.0%, 58.5%, and 54.9%, respectively. Early PersAF had a relatively favorable survival rate and a narrow P-wave duration of restoring sinus rhythm compared with that of PersAF lasting more than three months (P < 0.05). The multivariate Cox regression analysis revealed that PersAF duration and left atrial anteroposterior diameter ≥ 42 mm were the risk factors for atrial fibrillation recurrence after CBA [hazard ratio (HR) = 1.89, 95% CI: 1.01–1.4, P = 0.042; HR = 3.6, 95% CI: 2.4–5.4, P < 0.001, respectively]. The blanking period recurrence predicted the long-term recurrence (P < 0.0001).  CONCLUSIONS  CBA of PersAF had safety and efficacy to reach de novo PVI. The PersAF duration and left atrial size were risk factors for atrial fibrillation recurrence after CBA. Blanking period recurrence was associated with long-term recurrence.
Ran XU, Jian WU, Chun-Jie YANG, Le KANG, Yu-Yao JI, Chang LI, Zhi-Wen DING, Yun-Zeng ZOU
 doi: 10.11909/j.issn.1671-5411.2022.10.016
Abstract(55) FullText HTML(22) PDF (4)
 BACKGROUND  The molecular mechanisms of heart failure (HF) remain poorly understood. Studies have increasingly found circular RNA (circRNA) exists in heart. The aim of this study is to acquire potential functions of circRNAs in HF.  METHODS & RESULTS  We integrated RNA sequencing data to identify the characteristics of circRNAs expressed in heart and found that most circRNAs screened were < 2000 nt (89%); moreover, Chromosome 1 and Y contained the largest and least number of circRNAs (10.59% and 0.2%), respectively. Subsequently, a total of 238 differentially expressed circRNAs (DECs) were found and 203 host genes were discovered after excluding duplicate host genes and intergenic circRNAs. However, only 4 of 203 host genes of DECs were checked in differentially expressed genes (DEGs) of HF. Another, Gene Oncology (GO) analysis of DECs host genes was performed to elucidate the underlying pathogenesis of HF, suggesting that binding and catalytic activity accounted for a great part of DECs. The pathways related to immune system, metabolism and signal transduction were significantly enriched. Additionally, 1052 potentially regulated miRNAs from the top 40 DECs were collected to construct a circRNA–miRNA network and found that 470 miRNAs can be regulated by multiple circRNA, while others were regulated by a single circRNA. And further comparison with the top 10 mRNAs and their targeted miRNAs in HF showed DDX3Y and UTY were regulated by the most and least circRNA, respectively. Finally, four selected randomly DECs were validated by qRT-PCR.  CONCLUSION  These data showed that circRNAs have species and tissue specific expression features; although circRNAs expression independent on host genes, same types of genes between DECs and DEGs worked in HF. CircRNAs could regulate miRNAs as molecular sponges. Our data would enhance understanding of the important roles of circRNAs and lay a foundation for future investigations of HF molecular functions.
Latest News
We would delightedly report that the 2020 SCI impact factor of Journal of Geriatric Cardiology(JGC,ISSN 1671-5411/ CN 11-5329/R) has increased from 2.491 to 3.327, according to the 2020 Journal Citation Reports (InCites, Clarivate Analytics), ranking 33/53 and 65/142 in the fields of Geriatrics & Gerontology and Cardiac & Cardiovascular Systems, respectively. Show more
Press releases Press office Contact us